Print Page | Sign In | Join
Business Wire Life Sciences News (US)
Share |

Celgene Corporation Announces Appointment of Jonathan Biller as Executive Vice President and General Counsel Following the Departure of Gerald F. MasoudiOpen in a New Window

SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ:CELG) today announced the appointment of Jonathan Biller as Executive Vice President and General Counsel effective July 3, 2018. Mr. Biller will be responsible for global legal strategy and will serve on the company's Executive Committee. Mr. Biller will succeed Gerald F. Masoudi, Celgene's Executive Vice President and General Counsel since 2015. Mr. Masoudi is leaving Celgene to return to Washington, D.C. with his family and assume the

 

The iBIO Institute EDUCATE Center Hosts Third Annual STEMgirls Summer Camp at Andrew Cooke Magnet Elementary SchoolOpen in a New Window

CHICAGO--(BUSINESS WIRE)--Today, the iBIO Institute EDUCATE Center kicked off its third annual STEMgirls Summer Camp hosted at Andrew Cooke Magnet Elementary School in Waukegan. This week-long learning experience provides 125 young girls (grades 3-8) with opportunities to learn more about careers in science, technology, engineering and mathematics (STEM) through challenging and fun hands-on activities. Campers will take part in a wide range of activities throughout the week, using engineering a

 

Anika Therapeutics Announces Top-Line Results from CINGAL 16-02 Clinical Trial in Knee OsteoarthritisOpen in a New Window

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (HA) technology platform, today announced results from its CINGAL® 16-02 clinical trial, an active-comparator Phase III study being conducted to support U.S. registration. CINGAL has previously been evaluated in a placebo-controlled Phase III clinical trial (13-01) that demonstrated safe

 

Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development PlanOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today provided an update on the development plan for KPI-121 0.25%, which if approved could be the first FDA-approved product for the short-term treatment of dry eye disease. The Company announced that it plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) during the second half of 2018. The NDA will include data from three clinical trials studying approximately 2000 patients, incl

 

Apollo Endosurgery, Inc. Announces Commencement of Public Offering of Common StockOpen in a New Window

AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. Announces Commencement of Public Offering of Common Stock

 

Decibel Therapeutics Closes $55 Million Series C FinancingOpen in a New Window

BOSTON--(BUSINESS WIRE)--Decibel Therapeutics, a company dedicated to the discovery and development of breakthrough medicines to treat hearing loss and hearing-related disorders, today announced that it has raised $55M in a Series C financing. All existing investors, including Third Rock Ventures, GV, SR One, and Regeneron Pharmaceuticals, participated in the round, and were joined by new investors including Foresite Capital, Bessemer Trust, Schroder Adveq, SCubed Capital, Longevity, and additi

 

Stimwave Appoints Industry Veteran Steven Amelio as Chief Financial OfficerOpen in a New Window

POMPANO BEACH, Fla.--(BUSINESS WIRE)--Stimwave LLC, a medical device manufacturer and independent research institute headquartered in South Florida, today announced the appointment of industry veteran Steven Amelio to the position of Chief Financial Officer (CFO). Amelio is a senior financial executive with 30 years of experience in the medical device industry. Over his 20 year career with United States Surgical Corporation, Tyco Healthcare Group LP and ultimately Covidien, PLC he rose through

 

Multiple Myeloma Research Foundation (MMRF) Receives Highest Rating from Charity Navigator for Exceptional Fiscal ManagementOpen in a New Window

NORWALK, Conn.--(BUSINESS WIRE)--The Multiple Myeloma Research Foundation (MMRF) received a 4-star rating from Charity Navigator, America's largest independent evaluator of charitable donations, for demonstrating strong financial health and commitment to accountability and transparency. This is the fifteenth time the MMRF has earned this coveted recognition. The coveted 4-star rating, the highest honor Charity Navigator bestows, indicates that “The Multiple Myeloma Research Foundation exceeds i

 

Healogics to Host Scientific Symposium on Diabetic Wound Healing InnovationsOpen in a New Window

JACKSONVILLE, Fla.--(BUSINESS WIRE)--#Education--Healogics to host scientific symposium on diabetic wound healing innovations

 

Judges Panel Announced for the $100,000 Hearst Health PrizeOpen in a New Window

NEW YORK & PHILADELPHIA--(BUSINESS WIRE)--#PopHealth--Hearst Health and the Jefferson College of Population Health announced the distinguished panel of judges for the 2019 $100,000 Hearst Health Prize.

 

OncLive® to Host State of the Science Summit™ to Discuss Updates From the 2018 Annual Oncology MeetingOpen in a New Window

CRANBURY, N.J.--(BUSINESS WIRE)--OncLive® to Host State of the Science Summit™ to Discuss Updates From the 2018 Annual Oncology Meeting

 

CIRCULOGENE’s Molecular Testing Can Potentially Improve Management of Advanced Ovarian Cancer PatientsOpen in a New Window

BIRMINGHAM, Ala.--(BUSINESS WIRE)--#CIRCULOGENE--Researchers use CIRCULOGENE molecular testing to identify multiple mutations in advanced ovarian cancer patients following chemotherapy and surgery

 

Hilary Krane Joins the Gordon and Betty Moore Foundation Board of TrusteesOpen in a New Window

PALO ALTO, Calif.--(BUSINESS WIRE)--The Gordon and Betty Moore Foundation today announced the election of a new trustee, Hilary Krane, executive vice president, chief administrative officer and general counsel for NIKE, Inc. “With her expertise in organizational governance, leadership and understanding of the complex and dynamic global marketplace, Hilary brings a valuable perspective to our board of trustees,” said Harvey V. Fineberg, M.D., Ph.D., president of the foundation. “We are delighted

 

CURE® Media Group Honored in 20th Anniversary Digital Health Awards® Spring 2018 SessionOpen in a New Window

CRANBURY, N.J.--(BUSINESS WIRE)--CURE® Media Group Honored in 20th Anniversary Digital Health Awards® Spring 2018 Session

 

Pharmacy First/Third Party Station Unveils New Corporate IdentityOpen in a New Window

OVERLAND PARK, Kan.--(BUSINESS WIRE)--#corporateidentity--Pharmacy First/Third Party Station unveils new corporate identity, underscores commitment to independent pharmacies.

 

Inspection Services Labs in San Jose and Ohio Now Fully Equipped with Non-Destructive Testing TechnologyOpen in a New Window

HUDSON, Ohio--(BUSINESS WIRE)--Yxlon has completed installation of its latest technology systems in the company’s two Inspection Services facilities in North America open for customer trials and outsourced inspection contracting. Comet’s Lab One facility in San Jose, California, and Yxlon’s Non-Destructive Testing facility in Hudson, Ohio, now offer customers the ability to send samples for Non-Destructive Test (NDT) contract services, as well as provide an opportunity to conduct trials and eva

 

Pfizer Invites Public To View And Listen To Webcast Of July 31 Conference Call With AnalystsOpen in a New Window

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, July 31, 2018. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Second Quarter 2018 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on acc

 

IPS HEART, Resident of Johnson & Johnson Innovation, Uses Human Stem Cells for the First Time to Actually Reverse Heart Attack DamageOpen in a New Window

HOUSTON--(BUSINESS WIRE)--IPS HEART, resident of Johnson & Johnson Innovation, JLABS is pioneering the use of IPS cellular therapy for the replacement of heart tissue after heart attack, heart failure and duchenne cardiomyopathy. Recent results were presented at the 82nd Annual Scientific Meeting of the Japanese Circulation Society showing over 66% ejection fraction (EF) improvement after 90 days in a mouse model of heart attack treated with our human derived IPS HEART cardiomyocytes. These

 

Vitals Announces New Data Analytics DivisionOpen in a New Window

LYNDHURST, N.J.--(BUSINESS WIRE)--In a major strategic move, Vitals announced the formation of a new division, Vitals 360. This new division will focus on developing and advancing innovative data, quality and predictive analytics technologies to extend Vitals’ cost and engagement solutions, as well as to establish new capabilities that enable health plans to execute on their provider network strategies more effectively and efficiently. Network strategy is at the heart of any health care payer o

 

Mellitus Health to Present Clinical Research Findings at American Diabetes Association 78th Scientific SessionsOpen in a New Window

LOS ANGELES--(BUSINESS WIRE)--#2108ADA--Mayer B. Davidson, MD, CMO of Mellitus Health, to present clinical research findings at American Diabetes Association 78th Scientific Sessions

 

Pharmatech Appoints New Chief Financial OfficerOpen in a New Window

HAYWARD, Calif.--(BUSINESS WIRE)--#PDA--Pharmatech Associates expands its executive team with the appointment of Michaela Mueller as CFO.

 

Daniel Schlessinger Elected Chair of Hebrew University Board of GovernorsOpen in a New Window

CHICAGO--(BUSINESS WIRE)--The law firm of Jaszczuk P.C. is exceptionally proud to announce that the Board of Governors of Hebrew University has unanimously elected Daniel I. Schlessinger, a partner at Jaszczuk P.C., as the University’s next Chair of the Board of Governors. The Hebrew University of Jerusalem was established in 1918 by, among others, Albert Einstein, and is consistently ranked among the top universities in the world. Serving over 23,000 students from 90 countries, the university

 

Bay Labs’ EchoMD AutoEF Software Receives FDA Clearance for Fully Automated AI Echocardiogram AnalysisOpen in a New Window

SAN FRANCISCO--(BUSINESS WIRE)--#AI--Bay Labs' EchoMD AutoEF AI algorithms received FDA 510(k) clearance for fully automated clip selection and ejection fraction calculation

 

TransPerfect Life Sciences to Lead Collaboration Workshop and Release New Trial Interactive E-Clinical Technology at DIA 2018Open in a New Window

BOSTON--(BUSINESS WIRE)--TransPerfect Life Sciences, a leading provider of services and technologies to support global product development for the life sciences industry, today announced highlights of its presence at DIA 2018, including a workshop entitled Real-Life Strategies for Collaborative Stakeholder Management as well as the release of version 9.2 of the award-winning Trial Interactive e-clinical platform. The workshop will be held June 27 at 2:00 PM and will be led by Christine Morris,

 

Synthace Named a 2018 Cool Vendor in Life Sciences by GartnerOpen in a New Window

LONDON--(BUSINESS WIRE)--#Automation--Synthace Ltd., the company behind the leading cloud software platform for automating and improving the success rate of biological research and development, today announced it has been recognized in Gartner, Inc.'s "Cool Vendors in Life Sciences" report published on June 6, 2018. The companies named in this report represent a look into the new and innovative vendors, products and services in the global Life Sciences market. Gartner’s report points out, “Big data and adva

 

Humacyte Appoints Jeffrey Lawson MD, PhD as President and Chief Executive OfficerOpen in a New Window

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Humacyte, an innovator in biotechnology and regenerative medicine, announced today that Jeffrey Lawson MD, PhD has been appointed President and Chief Executive Officer. Carrie S. Cox has assumed the role of Executive Chairman. Dr. Lawson, an innovator, scientist and vascular surgeon has been involved in the development of Humacyte’s vascular technologies, in collaboration with his career-long research partner and Humacyte founder Dr. Laura Niklason

 

FEops Strengthens Management TeamOpen in a New Window

GENT, Belgium--(BUSINESS WIRE)--FEops strengthens management team

 

Varsity Brands, the Leader in Elevating Student Experiences in Sports, Spirit, and Achievement, to Be Acquired by Bain Capital Private EquityOpen in a New Window

DALLAS--(BUSINESS WIRE)--Varsity Brands, the market leader in team sports, school spirit and achievement recognition, today announced the signing of a definitive agreement to be acquired by Bain Capital Private Equity, a leading global private investment firm. Varsity Brands is being acquired from Charlesbank Capital Partners and funds managed and/or advised by Partners Group, which purchased the company in 2014. Financial terms were not disclosed. Founded in 1974, Varsity Brands elevates the s

 

Occidental Petroleum and White Energy to Study Feasibility of Capturing CO2 for Use in Enhanced Oil Recovery OperationsOpen in a New Window

HOUSTON & PLANO, Texas--(BUSINESS WIRE)--Occidental Petroleum and White Energy announce first carbon capture project since passage of the FUTURE Act

 

JenaValve Technology Implants Initial Patients in CE Mark Study for the Treatment of Severe Aortic Regurgitation with Next-Generation TAVR SystemOpen in a New Window

IRVINE, Calif.--(BUSINESS WIRE)--JenaValve Technology, Inc., a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced initiation of patient enrollment and implantations associated with the CE Mark study of its next generation JenaValve Pericardial TAVR System using the CoronatixTM Transfemoral Delivery Catheter for the percutaneous treatment of patients with symptomatic, severe aortic regurgitation (AR). The JenaValve Pericardial TAVR

 

Hu-manity.co Joins Global Pharmaceutical Companies to Discuss Patient Data as Patient Property on BlockchainOpen in a New Window

PRINCETON, N.J.--(BUSINESS WIRE)--Hu-manity.co, a company designed to create decentralized human rights using proprietary technology and legal innovations on blockchains has been invited by Paul Simms, Chairman of eyefoprpharma to join the global pharmaceutical conversation around the impact of blockchain on the relationship between the pharmaceutical industry, patients and patient data. The four-person discussion moderated by Mr. Simms will be streamed live beginning at 09:00AM EDT Wednesday J

 

NorthStar Medical Radioisotopes Announces Mo-99 Supply Update Presentation at Upcoming Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual MeetingOpen in a New Window

BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC announces Mo-99 supply presentation and RadioGenix(TM) System update at upcoming SNMMI conference.

 

Elligo and Partners Participate in Federal Real-World Evidence ProjectOpen in a New Window

AUSTIN, Texas--(BUSINESS WIRE)--Elligo, Flatiron Health and the University of Chicago will partner in a federal project led by the FDA to develop a common data architecture.

 

Advanced BioNutrition Corp. Announces Leadership AppointmentsOpen in a New Window

COLUMBIA, Md.--(BUSINESS WIRE)--Advanced BioNutrition Corp. Announces Leadership Appointments

 

ZipLine Medical Closes $9 Million Growth Financing Led by Existing Investor MVM Partners LLPOpen in a New Window

CAMPBELL, Calif.--(BUSINESS WIRE)--ZipLine Medical closes $9 million in growth financing to support its portfolio of unique skin and wound closure devices.

 

SetPoint Medical Reports Positive Long-term Results from its Clinical Study of Bioelectronic Medicine to Treat Rheumatoid ArthritisOpen in a New Window

VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical announced positive long-term data for its first-in-human study using bioelectronic medicine for rheumatoid arthritis (RA) at EULAR.

 

Sickle Cell Disease Association of America, Inc. Partners With Emmaus Life Sciences, Inc.Open in a New Window

BALTIMORE--(BUSINESS WIRE)--Sickle Cell Disease Association of America, Inc. Partners with Emmaus Life Sciences, Inc.

 

Aptar Announces Leadership AppointmentsOpen in a New Window

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR) today announced the appointment of Gael Touya to President, Aptar Pharma effective September 1, 2018. Touya, who had been President, Aptar Food + Beverage since January of 2016, will continue to report to CEO Stephan Tanda. Touya succeeds Salim Haffar who has announced he will depart Aptar at the beginning of September to become CEO of a privately-held provider of outsourced pharmaceutical services. Touya, whose career with Aptar

 

Alcresta Therapeutics Announces RELiZORB® iMMOBILIZED LIPASE CARTRIDGE has been Issued a Unique Q-Code (Q9994) by CMSOpen in a New Window

WARREN, N.J.--(BUSINESS WIRE)--Alcresta Therapeutics, Inc. today announced the issuance of a unique Q-code by CMS for its digestive enzyme cartridge RELiZORB. RELiZORB (iMMOBILIZED LIPASE) CARTRIDGE is an in-line digestive enzyme cartridge and is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula. The code, Q9994, is effective July 1, 2018. CMS has instructed Medicare Administrative Contractors to add Q9994 to the relevant co

 

SAMDI Tech Inc. Awarded Phase I Small Business Innovation Research Grant From NIHOpen in a New Window

CHICAGO--(BUSINESS WIRE)--SAMDI Tech Inc. is pleased to announce it has received a Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH).

 

Dicerna Set to Join the Russell 3000® and Russell 2000® IndexesOpen in a New Window

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna today announced that the Company is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index.

 

Humana and Walgreens to Offer Senior-focused Services in Kansas City Area via Primary Care Clinics and In-store Health Navigation SupportOpen in a New Window

LOUISVILLE, Ky. & DEERFIELD, Ill.--(BUSINESS WIRE)--Leading health and well-being company Humana Inc. (NYSE: HUM) and Walgreens, a provider of trusted pharmacy services and care in communities since 1901, are teaming up to provide easier access to primary care and other services for seniors, as part of the companies’ ongoing and shared commitment to the health and well-being of the Kansas City community. The collaboration will establish a senior-focused neighborhood approach to health that brin

 

Novus Therapeutics Receives FDA Guidance at Type C Meeting for OP-02 in the Treatment and Prevention of Otitis MediaOpen in a New Window

IRVINE, Calif.--(BUSINESS WIRE)--FDA Meeting

 

Global Coatings for Medical Devices Market 2016-2024 - Strategic Business Report Covering Annual Estimates and Forecasts - ResearchAndMarkets.comOpen in a New Window

DUBLIN--(BUSINESS WIRE)--The "Coatings for Medical Devices - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. This report analyzes the worldwide markets for Coatings for Med

 

Founders Fund Leads $36 Million Financing Round in Emulate, Inc.Open in a New Window

BOSTON--(BUSINESS WIRE)--Emulate has secured a $36 million Series C financing round led by Founders Fund for commercialization of the Human Emulation System™.

 

AstraZeneca to Share Latest Data from an Industry-Leading Portfolio That Aims to Advance Clinical Understanding of Diabetes and CV Risk Management at ADA 2018Open in a New Window

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and its global biologics research and development arm, MedImmune, will present 45 abstracts including seven late-breaking data disclosures from the Company’s Cardiovascular (CV), Renal and Metabolism (CVRM) therapy area at the American Diabetes Association’s (ADA) 78th Scientific Sessions in Orlando, Florida, June 22-26, 2018. This latest research will help to inform clinical practice with FARXIGA® (dapagliflozin) and BYDUREON® (exenatide extended-

 

PROCEPT BioRobotics Named 2018 MedTech Breakthrough Award WinnerOpen in a New Window

REDWOOD SHORES, Calif.--(BUSINESS WIRE)--#BPH--PROCEPT BioRobotics has won the "Best Healthcare Robotics Solution" award from MedTech Breakthrough for its AquaBeam System for the treatment of BPH.

 

Can-Fite Updates on Status of Phase II Advanced Liver Cancer TrialOpen in a New Window

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today provided an update on its Phase II clinical trial with drug candidate Namodenoson (CF102) in the treatment of advanced hepatocellular carcinoma (HCC) in patients whose disease has progressed on sorafenib therapy. Can-Fite anticipates analyzing the results of t

 

Corindus Promotes Doug Teany to Chief Operating OfficerOpen in a New Window

WALTHAM, Mass.--(BUSINESS WIRE)--Corindus promotes Doug Teany to COO

 

Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in the U.S.Open in a New Window

NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Submits Application for Priority Review and Approval of ALXN1210 as a Treatment for Patients with PNH in the U.S.

 

Tower MSA Partners’ Rita Wilson and Other NAMSAP Directors Discussed Opioids and MSAs at the National Council of Self-Insurers ConferenceOpen in a New Window

BATON ROUGE, La.--(BUSINESS WIRE)--NAMSAP officers discussed opioids and MSAs at the National Council of Self-Insurers Conference.

 

Insulet to Unveil New Omnipod® DASHTM System and Present Innovative Research at the American Diabetes Association's 78th Scientific SessionsOpen in a New Window

BILLERICA, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced it will showcase its recently FDA cleared Omnipod DASHTM Insulin Management System (Omnipod DASH System), during the American Diabetes Association (ADA) 78th Scientific Sessions at the Orange County Convention Center in Orlando, Florida June 22-25, 2018. Insulet will also have

 

NantKwest Names Sonja Nelson Chief Financial OfficerOpen in a New Window

CULVER CITY, Calif.--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq: NK) today announced the elevation of Sonja Nelson, chief accounting officer for the company, to the role of Chief Financial Officer (CFO). Nelson, who first joined NantKwest in 2015, as the top financial officer at NantKwest, a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using natural killer cells to treat cancer, infectious diseases and inflammatory diseases. Nelson succeeds R

 

RENÚ® Voice and RENÚ® Gel Now Available in the US Exclusively from InHealth® TechnologiesOpen in a New Window

CARPINTERIA, Calif.--(BUSINESS WIRE)--RENÚ® Voice and RENÚ® Gel Now Available in the US Exclusively from InHealth® Technologies

 

Dr. Reddy's Laboratories Announces the Launch of Levetiracetam in Sodium Chloride Injection in the U.S. MarketOpen in a New Window

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Levetiracetam in Sodium Chloride Injection, 500 mg/100 mL (5 mg/mL), 1,000 mg/100 mL (10 mg/mL), and 1,500 mg/100 mL (15 mg/mL) single-dose infusion bags, a therapeutic equivalent generic version of HQ Specialty Pharma Corporation’s Levetiracetam in Sodium Chloride Injection, approved by the U.S. Food and Drug Administration (USFDA). The

 

U.S. Patent Office Grants First Charpentier/Doudna Patent Covering CRISPR/Cas9 Gene EditingOpen in a New Window

DUBLIN--(BUSINESS WIRE)--ERS Genomics announced today that the U.S. Patent and Trademark Office (USPTO) has granted Dr. Emmanuelle Charpentier, ERS Genomics’ co-founder, together with the University of California and University of Vienna, their first U.S. patent with claims covering the use of CRISPR/Cas9 technology for gene editing. The patent covers the use of an optimized guide RNA format in all environments including human cells. The USPTO deemed the claims in this patent unrelated to the o

 

Karuna Receives $8 Million Wellcome Trust Award to Advance First-in-Class Phase 2 Clinical Program in SchizophreniaOpen in a New Window

BOSTON--(BUSINESS WIRE)--Karuna receives $8 million award from the Wellcome Trust.

 

Gary M. Munsinger Has Resigned from RCT’s Board of DirectorsOpen in a New Window

TUCSON, Ariz.--(BUSINESS WIRE)--Research Corporation Technologies (RCT) announces that Gary M. Munsinger, Ph.D., resigned from its Board of Directors and all positions associated with RCT, effective May 15, 2018. Dr. Munsinger was a founding Director of RCT in 1987 and served as RCT’s CEO from its founding in 1987 to May 2005. In June 2005, he became Chairman of the Board, a position he held until his resignation in May. He is succeeded by John W. McIntyre, who previously served as RCT’s Vice C

 

About BioFlorida

BioFlorida represents nearly 6,000 establishments and research organizations in the biopharmaceutical, medical technology and bioagriculture sectors that collectively employ nearly 83,000 Floridians.

 

Members of the BioFlorida network include emerging and established life science companies, universities, research institutions, hospitals, medical centers, incubators, economic development agencies, investors and service providers.

 

Email us for a regional Chapter sponsorship.

Connect